Yara Catoira-Boyle, MD
Ophthalmology · Indianapolis, INNPI 1396746459
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.4% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 29.8% of the total. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $47.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Alcon$2K
- Aerie Pharmaceuticals, Inc.$1K
- Glaukos Corporation$963
- Sight Sciences, Inc.$392
- Nova Eye, Inc.$240
- plus $1K from 18 others
What the payments were for
- Consulting fees$5006%
- Food & beverage$7,80090%
- Education$681%
- Gifts$451%
- Entertainment$2183%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $2,573 |
| Alcon | 46 | $2,002 |
| Aerie Pharmaceuticals, Inc. | 10 | $1,035 |
| Glaukos Corporation | 9 | $963 |
| Sight Sciences, Inc. | 7 | $392 |
| Nova Eye, Inc. | 2 | $240 |
| Harrow Eye, LLC | 3 | $221 |
| Sun Pharmaceutical Industries Inc. | 8 | $210 |
| Janssen Global Services, LLC | 1 | $177 |
| Tarsus Pharmaceuticals, Inc. | 3 | $159 |
| Kala Pharmaceuticals, Inc. | 7 | $114 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $86 |
| Amgen | 4 | $82 |
| Ocular Therapeutix, Inc. | 2 | $79 |
| NEW World Medical,inc. | 4 | $69 |
| Bausch & Lomb Americas Inc. | 2 | $48 |
| Beaver-visitec International, Inc. | 1 | $39 |
| Eyepoint US, Inc. | 2 | $30 |
| Novartis | 1 | $27 |
| Thea Pharma Inc. | 1 | $20 |
| Carl Zeiss Meditec USA, Inc. | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Ivantis, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$968
- XEN GLAUCOMA TREATMENT SYSTEM$753
- Hydrus Microstent$591
- iStent infinite Trabecular Micro-Bypass System Model iS3$345
- XEN$270
- Clareon PanOptix Pro$267
- Clareon$254
- DURYSTA$245
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$173
- LUMIGAN$150
- OMNI(R) SURGICAL SYSTEM (US)$149
- LenSx$147
- iDose$146
- iDoseTR$139
- iStent Infinite$139
- IHEEZO$125
- TRIESENCE$125
- Rhopressa$118
How this compares
$8,631 in reported general payments places this provider in the 90th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 191 | $83,177 |
| LumiganBimatoprost | 144 | $78,411 |
| RestasisCyclosporine | 55 | $55,715 |
| CombiganBrimonidine Tartrate/Timolol | 109 | $45,561 |
| RocklatanNetarsudil Mesylat/Latanoprost | 83 | $38,381 |
| XiidraLifitegrast | 45 | $37,121 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 81 | $16,238 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 51 | $15,901 |
| MieboPerfluorohexyloctane/Pf | 14 | $14,289 |
| Alphagan PBrimonidine Tartrate | 29 | $13,292 |
| Brimonidine Tartrate | 261 | $11,261 |
| Prednisolone Acetate | 238 | $9,110 |
| Brinzolamide | 35 | $7,415 |
| VyzultaLatanoprostene Bunod | 17 | $6,481 |
| Cyclosporine | 25 | $6,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,573 | $192,979337 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $1,035 | $121,558274 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $48 | $57,89176 claims |
| AlconSimbrinza | $2,002 | $15,90151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Indianapolis
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Michael OrrIndianapolis$26K
- Matthew FengIndianapolis$22K
- John LindIndianapolis$20K
- Shaohui LiuIndianapolis$19K
- John LatonaIndianapolis$18K
- William WhitsonIndianapolis$15K
- Thierry WilbrandtIndianapolis$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.